Mammalian Target of Rapamycin as a Target in Hematological Malignancies

Current Problems in Cancer

Volumn 32, Issue 4, 2008, Pages 161-177

  Abdel Karim, Isam A ^a   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; BORTEZOMIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; IMATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PROTEIN KINASE B; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TEMSIROLIMUS; VINCRISTINE; VORINOSTAT;

ACUTE KIDNEY FAILURE; ACUTE LEUKEMIA; ADD ON THERAPY; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG BINDING; DRUG HALF LIFE; DYSPNEA; ENZYME ACTIVITY; FATIGUE; FOLLITROPIN BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; LUTEINIZING HORMONE BLOOD LEVEL; LYMPHOMA; MACULOPAPULAR RASH; MANTLE CELL LYMPHOMA; MONOTHERAPY; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OLIGOSPERMIA; PATHOPHYSIOLOGY; PLEURA EFFUSION; PNEUMONIA; PROTEINURIA; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; SYNCOPE; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA;

ANTIBIOTICS, ANTINEOPLASTIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIROLIMUS;

EID: 48949119272     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2008.05.001     Document Type: Article

References (123)

1. Meijer A.J., and Dubbelhuis P.F. Amino acid signalling and the integration of metabolism. Biochem Biophys Res Commun 313 2 (2004) 397-403
2. Long X., Muller F., and Avruch J. TOR action in mammalian cells and in Caenorhabditis elegans. Curr Top Microbiol Immunol 279 (2004) 115-138
3. Gingras A.C., Raught B., and Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol 279 (2004) 169-197
4. Fingar D.C., Richardson C.J., Tee A.R., et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24 1 (2004) 200-216
5. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. [see comment]. Cell 103 2 (2000) 253-262
6. Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15 7 (2001) 807-826
7. Sabers C.J., Martin M.M., Brunn G.J., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270 2 (1995) 815-822
8. Sabatini D.M., Erdjument-Bromage H., Lui M., et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78 1 (1994) 35-43
9. Chiu M.I., Katz H., and Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 91 26 (1994) 12574-12578
10. Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 6483 (1994) 756-758
11. Jacinto E., and Hall M.N. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4 2 (2003) 117-126 [Published erratum appears in Nat Rev Mol Cell Biol 2003;4(3):249.]
12. Abraham R.T. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 111 1 (2002) 9-12
13. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31 5 (1998) 335-340 [Reprint in Clin Biochem 2006;39(5):484-9, PMID: 16783879.]
14. Vezina C., Kudelski A., and Sehgal S.N. Rapamycin (AY-22989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 28 10 (1975) 721-726
15. Sehgal S.N., Baker H., and Vezina C. Rapamycin (AY-22989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 28 10 (1975) 727-732
16. Calne R.Y., Collier D.S., Lim S., et al. Rapamycin for immunosuppression in organ allografting. [see comment]. Lancet 2 8656 (1989) 227
17. Augustine J.J., Bodziak K.A., and Hricik D.E. Use of sirolimus in solid organ transplantation. Drugs 67 3 (2007) 369-391
18. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs R D 5 6 (2004) 363-367
19. Steffel J., Latini R.A., Akhmedor A., et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 13 (2005) 2002-2011
20. Eng C.P., Sehgal S.N., and Vezina C. Activity of rapamycin (AY-22989) against transplanted tumors. J Antibiot 37 10 (1984) 1231-1237
21. Houchens D.P., Ovejera A.A., Riblet S.M., et al. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 19 6 (1983) 799-805
22. Douros J., and Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 8 1 (1981) 63-87
23. Huang S., and Houghton P.J. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3 4 (2003) 371-377
24. Dennis P.B., and Thomas G. Quick guide: target of rapamycin. Curr Biol 12 8 (2002) R269
25. Sarkaria J.N., Busby E.C., Tibbetts R.S., et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58 19 (1998) 4375-4382
26. Yuille M.A., and Coignet L.J. The ataxia telangiectasia gene in familial and sporadic cancer. Recent Results Cancer Res 154 (1998) 156-173
27. Kim D.H., Sarbassor D.D., Ali S.M., et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11 4 (2003) 895-904
28. Hara K., Maruki Y., Long X., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 2 (2002) 177-189
29. Kim D.H., Sarbassor D.D., Ali S.M., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 2 (2002) 163-175
30. Yonezawa K., Tokunaga C., Oshiro N., et al. Raptor, a binding partner of target of rapamycin. Biochem Biophys Res Commun 313 2 (2004) 437-441
31. Harris T.E., and Lawrence Jr. J.C. TOR signaling. Science's Stke [Electronic Resource]: Signal Transduction Knowledge Environment, 2003 212 (2003) re15
32. Nojima H., Tokunaga C., Eguchi S., et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278 18 (2003) 15461-15464
33. Proud C.G. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 313 2 (2004) 429-436
34. Yonezawa K., Yoshino K.I., Tokunaga C., et al. Kinase activities associated with mTOR. Curr Top Microbiol Immunol 279 (2004) 271-282
35. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 14 (2004) 1296-1302
36. Sarbassov D.D., Guertin D.A., Ali S.M., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 5712 (2005) 1098-1101
37. Motzer R.J., Hudes G.R., Curti B.D., et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25 25 (2007) 3958-3964
38. Mabuchi S., Altomare D.A., Connolly D.C., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67 6 (2007) 2408-2413
39. Karbowniczek M., Spittle C.S., Morrison T., Wu H., and Henske E.P. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 128 4 (2008) 980-987
40. Johnson B.E., Jackman D., and Janne P.A. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 13 15 (2007) s4628-s4631
41. Fouladi M., Laningham F., Wu J., et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25 30 (2007) 4806-4812
42. Costa L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 33 1 (2007) 78-84
43. Cho D., Signoretti S., Regan M., et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 13 2 (2007) 758s-763s
44. Yee K.W., Zeng Z., Konoplera M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12 17 (2006) 5165-5173
45. Hynes N.E., and Boulay A. The mTOR pathway in breast cancer. J Mammary Gland Biol Neoplasia 11 1 (2006) 53-61
46. Panwalkar A., Verstovsek S., and Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100 4 (2004) 657-666
47. Dancey J.E. mTOR inhibitors in hematologic malignancies. Clin Adv Hematol Oncol 1 7 (2003) 419-423
48. Herberger B., Puhalla H., Lehnert M., et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 13 16 (2007) 4795-4799
49. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 1 (2007) 9-22
50. Hutson T.E., and Figlin R.A. Evolving role of novel targeted agents in renal cell carcinoma. Oncology 21 10 (2007) 1175-1180
51. Brown R.E., Zhang P.L., Lun M., et al. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci 36 3 (2006) 273-282
52. Clark P.E. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 17 5 (2007) 331-336
53. Kobayashi S., Kishimoto T., Kamata S., et al. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98 5 (2007) 726-733
54. Huber S., Bruns C.J., Schmid G., et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 71 8 (2007) 771-777
55. Nathan C.O., Amirghahari N., Rong X., et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 67 5 (2007) 2160-2168
56. Buck E., Eyzaguirre A., Brown E., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5 11 (2006) 2676-2684
57. Chollet P., Abrial C., Tacca O., et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 7 4 (2006) 336-338
58. Martelli A.M., Tazzari P.L., Evangelisti C., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 14 19 (2007) 2009-2023
59. Follo M.Y., Mongiorgi S., Bosi C., et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 67 9 (2007) 4287-4294
60. Xu Q., Thompson J.E., and Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106 13 (2005) 4261-4268
61. Wanner K., Hipp S., Oelsner M., et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134 5 (2006) 475-484
62. Vega F., Medeiros L.J., Leventaki V., et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66 13 (2006) 6589-6597
63. Kawamata N., Chen J., and Koeffler H.P. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 110 7 (2007) 2667-2673
64. Huyghe E., Zairi A., Nohra J., et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 20 4 (2007) 305-311
65. Deutsch M.A., Kaczmarek I., Huber S., et al. Sirolimus-associated infertility: case report and literature review of possible mechanisms. Am J Transplant 7 10 (2007) 2414-2421
66. Pallet N., Thervet E., Legendre C., et al. [Nephrotoxicity of sirolimus: experimental and clinical data]. Nephrol Ther 2 4 (2006) 183-190
67. Rangan G.K. Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 29 12 (2006) 1153-1161
68. Boni J., Leister C., Burns J., et al. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. J Clin Pharmacol 47 11 (2007) 1430-1439
69. Duran I., Siu L.L., Oza A.M., et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42 12 (2006) 1875-1880
70. Tenderich G., Fuchs U., Zittermann A., et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 21 4 (2007) 536-543
71. Fruman D.A., Wood M.A., Gjertson C.K., et al. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 25 2 (1995) 563-571
72. Luo Y., Marx S.O., Kiyokawa H., et al. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 16 12 (1996) 6744-6751
73. Shima H., Pende M., Chen Y., et al. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17 22 (1998) 6649-6659
74. Dilling M.B., Germain G.S., Dudkin L., et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 277 16 (2002) 13907-13917
75. Dennis P.B., Pullen N., Kozma S.C., et al. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 16 11 (1996) 6242-6251
76. Sugiyama H., Papst P., Gelfand E.W., et al. p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229. J Immunol 157 2 (1996) 656-660
77. Huang S., Shu L., Dilling M.B., et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 11 6 (2003) 1491-1501
78. Kurmasheva R.T., Huang S., and Houghton P.J. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 95 8 (2006) 955-960
79. Beamish H., Williams R., Chen P., et al. Rapamycin resistance in ataxia-telangiectasia. Oncogene 13 5 (1996) 963-970
80. Bertram P.G., Zeng C., Thorson J., et al. The 14-3-3 proteins positively regulate rapamycin-sensitive signaling. Curr Biol 8 23 (1998) 1259-1267
81. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 3 (2006) 1500-1508
82. Dumont F.J., Staruch M.J., Grammer T., et al. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. Cell Immunol 163 1 (1995) 70-79
83. Hammerman P.S., Fox C.J., Birnbaum M.J., et al. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 105 11 (2005) 4477-4483
84. Shi Y., Gera J., Hu L., et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62 17 (2002) 5027-5034
85. Peponi E., Drakos E., Reyes G., et al. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169 6 (2006) 2171-2180
86. Goy A., and Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma 7 suppl 5 (2007) S184-S191
87. Hipp S., Ringshausen I., Oelsner M., et al. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90 10 (2005) 1433-1434
88. Baumann P., Mandl-Weber S., Emmerich B., et al. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res 313 16 (2007) 3592-3603
89. Strömberg T., Dimberg A., Hammarberg A., et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103 8 (2004) 3138-3147
90. Yan H., Frost P., Shi Y., et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66 4 (2006) 2305-2313
91. Francis L.K., Alsayed Y., Leleu X., et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 12 22 (2006) 6826-6835
92. Avellino R., Romano S., Parasole R., et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106 4 (2005) 1400-1406
93. Thomas X. Emerging drugs for adult acute lymphoblastic leukaemia. Expert Opin Emerg Drugs 10 3 (2005) 591-617
94. Brown V.I., Fang J., Alcom K., et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 100 25 (2003) 15113-15118
95. Lal L., Li Y., Smith J., et al. Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 105 4 (2005) 1669-1677
96. Dos Santos C., Récher C., Demur C., et al. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia]. Bull Cancer 93 5 (2006) 445-447
97. Récher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105 6 (2005) 2527-2534
98. Récher C., Dos Santos C., Demur C., et al. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4 11 (2005) 1540-1549
99. Xu R.H., Pelicano H., Zhang H., et al. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19 12 (2005) 2153-2158
100. Yoon P., Giafis N., Smith J., et al. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 5 11 (2006) 2815-2823
101. Ly C., Arechiga A.F., Melo J.V., et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 63 18 (2003) 5716-5722
102. Burchert A., Wang Y., Cai D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19 10 (2005) 1774-1782
103. Mayerhofer M., Aichberger K.J., Florian S., et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J 19 8 (2005) 960-962
104. Parmar S., Smith J., Sassano A., et al. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 106 7 (2005) 2436-2443
105. Jundt F., Raetzel N., Müller C., et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 106 5 (2005) 1801-1807
106. Ringshausen I., Peschel C., and Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leuk Lymphoma 46 1 (2005) 11-19
107. Leseux L., Hamdi S.M., Al Saati T., et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108 13 (2006) 4156-4162
108. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 12 (2004) 2336-2347
109. Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12 19 (2006) 5755-5763
110. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 5 (2004) 909-918
111. Peralba J.M., DeGraffenreid L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9 8 (2003) 2887-2892
112. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 23 (2005) 5347-5356
113. Grube E., Gerckens U., and Buellesfeld L. Drug-eluting stents: clinical experiences and perspectives. Minerva Cardioangiol 50 5 (2002) 469-473
114. Majewski M., Korecka M., Kossev P., et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 97 8 (2000) 4285-4290
115. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 9 (2003) 847-858
116. Majewski M., Korecka M., Joergensen J., et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75 10 (2003) 1710-1717
117. Azzola A., Havry K.A., Chhajed P., et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 77 2 (2004) 275-280
118. Pascual J. Everolimus in clinical practice: renal transplantation. Nephrol Dial Transplant 21 suppl 3 (2006) iii18-iii23
119. Kirchner G.I., Meier-Wiedenbach I., and Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43 2 (2004) 83-95
120. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 1 (2004) 252-261
121. Haritunians T., Mori A., O'Kelly J., et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21 2 (2007) 333-339
122. Feldman E, Giles F, Roboz G, et al. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), Abstract 6631, 2005.
123. Rizzieri D.A., Feldman E., Moore J.O., et al. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. Blood 106 11 (2005) Abstract 2980